Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy

Christopher A. Warlick; Mohamad E. Allaf; H. Ballentine Carter

doi:10.1016/j.urolonc.2005.07.004

Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy

Christopher A. Warlick
, Mohamad E. Allaf
, H. Ballentine Carter

Urology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm³, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.

Original language	English (US)
Pages (from-to)	51-57
Number of pages	7
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/j.urolonc.2005.07.004
State	Published - Jan 2006

Bibliographical note

Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Curative intervention
Expectant management
Prostate cancer

Publisher link

10.1016/j.urolonc.2005.07.004

Find It

Find It at U of M Libraries

Cite this

@article{84c8c6db32fb42efbe4ae32efe116609,

title = "Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy",

abstract = "Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm3, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.",

keywords = "Curative intervention, Expectant management, Prostate cancer",

author = "Warlick, \{Christopher A.\} and Allaf, \{Mohamad E.\} and Carter, \{H. Ballentine\}",

year = "2006",

month = jan,

doi = "10.1016/j.urolonc.2005.07.004",

language = "English (US)",

volume = "24",

pages = "51--57",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Expectant treatment with curative intent in the prostate-specific antigen era

T2 - Triggers for definitive therapy

AU - Warlick, Christopher A.

AU - Allaf, Mohamad E.

AU - Carter, H. Ballentine

PY - 2006/1

Y1 - 2006/1

N2 - Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm3, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.

AB - Expectant treatment with curative intent for treatment of low-risk prostate cancer faces 3 challenges in the PSA era: (1) appropriate patient selection, (2) adequate surveillance strategies, and (3) identification of triggers for definitive intervention when cure is still possible. Men 65 years or older with T1c disease, prostate-specific antigen density <0.15 ng/ml/cm3, and favorable biopsy characteristics per the Epstein criteria currently appear to be the safest candidates for expectant treatment. Changes in biopsy characteristics are the most objective trigger for definitive therapy currently in use. Outcomes data are still required to determine the safety of expectant treatment for localized disease.

KW - Curative intervention

KW - Expectant management

KW - Prostate cancer

UR - https://www.scopus.com/pages/publications/30744453538

UR - https://www.scopus.com/pages/publications/30744453538#tab=citedBy

U2 - 10.1016/j.urolonc.2005.07.004

DO - 10.1016/j.urolonc.2005.07.004

M3 - Article

C2 - 16414495

AN - SCOPUS:30744453538

SN - 1078-1439

VL - 24

SP - 51

EP - 57

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 1

ER -

Expectant treatment with curative intent in the prostate-specific antigen era: Triggers for definitive therapy

Abstract

Bibliographical note

UN SDGs

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this